Zobrazeno 1 - 10 of 446 pro vyhledávání: '"Heijde, D. Van der"'
1
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
Autor: Mease, P., Heijde, D. van der, Kirkham, B., Schett, G., Orbai, A.M., Ritchlin, C., Merola, J.F., Pricop, L., James, D.A., Zhu, X., Ligozio, G.
Publikováno v: Arthritis Research and Therapy, 24(1). BMC
Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swoll
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddbd0667a6e5e9a450be81fdd5c8c9f2
http://hdl.handle.net/1887/3515291
Zobrazit plný text záznamu
2
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
Autor: Baraliakos, X., Deodhar, A., Dougados, M., Gensler, L.S., Molto, A., Ramiro, S., Kivitz, A.J., Poddubnyy, D., Oortgiesen, M., Vaux, T., Fleurinck, C., Shepherd-Smith, J., Loge, C. de la, Peyrecave, N. de, Heijde, D. van der
Publikováno v: Arthritis and Rheumatology. WILEY
Arthritis and Rheumatology
Objective To assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active ankylosing spondylitis (AS). Methods Patients with active AS who completed the dose-ranging, 48-week BE AGILE randomized controlled trial were
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5b2389ff3609fef6fee1161cf9335bdc
http://hdl.handle.net/1887/3503929
Zobrazit plný text záznamu
3
A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis
Autor: Burgos-Vargas, R., Loyola-Sanchez, A., Ramiro, S., Reding-Bernal, A., Alvarez-Hernandez, E., Heijde, D. van der, Vazquez-Mellado, J.
Publikováno v: Arthritis Research and Therapy, 24(1). BMC
Objective To assess the efficacy and safety of infliximab versus placebo in the treatment of patients with juvenile-onset spondyloarthritis (JoSpA). Methods Phase III, randomized, double-blind, placebo-controlled trial of 12 weeks that included patie
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02196b893a0273c800e1f9a76a9b9190
https://hdl.handle.net/1887/3458772
Zobrazit plný text záznamu
4
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy
Autor: Heijde, D. van der, Baraliakos, X., Sieper, J., Deodhar, A., Inman, R.D., Kameda, H., Zeng, X.F., Sui, Y.X., Bu, X.W., Pangan, A.L., Wung, P., Song, I.H.
Objectives: To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs). Methods: Ad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______202::c4bd50571ae37ba719e4c825840834af
https://hdl.handle.net/1887/3627565
Zobrazit plný text záznamu
5
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Autor: Mease, P.J., Rahman, P., Gottlieb, A.B., Kollmeier, A.P., Hsia, E.C., Xu, X.L., Sheng, S.H., Agarwal, P., Zhou, B., Zhuang, Y.L., Heijde, D. van der, McInnes, I.B., Discover-2 Study Grp
Publikováno v: The Lancet, 395(10230), 1126-1136. ELSEVIER SCIENCE INC
Background:\ud The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 subunit, significantly and safely improved psoriatic arthritis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87f56927a5078f174fa4d4b31a7cc05a
https://doi.org/10.1016/s0140-6736(20)30263-4
Zobrazit plný text záznamu
8
Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years
Autor: McInnes, I.B., Rahman, P., Gottlieb, A.B., Hsia, E.C., Kollmeier, A.P., Xu, X.L., Jiang, Y.S., Sheng, S.H., Shawi, M., Chakravarty, S.D., Heijde, D. van der, Mease, P.J.
Objective To assess long-term efficacy and safety of guselkumab, an interleukin-23 p19 subunit (IL-23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER-2 trial. Methods In the DISCOVER-2 trial, patients with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::84c5b3a9528c74672a63fbb923b4d8f1
https://hdl.handle.net/1887/3276429
Zobrazit plný text záznamu
10
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
Autor: Strand, V., Heijde, D. van der, Tanaka, Y., Keystone, E., Kremer, J., Zerbini, C.A.F., Cardiel, M.H., Cohen, S., Nash, P., Song, Y.W., Tegzova, D., Gruben, D., Wallenstein, G., Connell, C.A., Fleischmann, R., ORAL Scan Investigators
Publikováno v: Clinical and Experimental Rheumatology, 38(5), 848-857. CLINICAL & EXPER RHEUMATOLOGY
ObjectiveTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we present data from the completed Phase 3 randomised controlled trial (RCT) ORAL Scan (NCT00847613), which evaluated the impact of tofacitini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c4a580f04cbef9ee7ff646de139242e3
https://hdl.handle.net/1887/3182998
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje